• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

5-ARI recalled due to possible mislabeling

Article

Greenstone LLC has announced that it is voluntarily conducting a recall of medicines with lot number FI0510058-A on the label, including the 5-alpha-reductase inhibitor finasteride, 5 mg tablets (90-count).

Greenstone LLC has announced that it is voluntarily conducting a recall of medicines with lot number FI0510058-A on the label, including the 5-alpha-reductase inhibitor finasteride, 5 mg tablets (90-count).

The recall also includes citalopram (Celexa), 10 mg (100-count), which is used to treat depression.

The recall is due to the possibility that a third-party manufacturer has placed incorrect labels on the bottles; specifically, bottles that are labeled as citalopram lot number FI0510058-A may contain finasteride, which is indicated for treatment of BPH. This is the only lot number being recalled, and no other lots or markets are believed to be impacted.

Bottles of either citalopram or finasteride with lot number FI0510058-A should be returned to the pharmacist, according to a statement from Greenstone.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.